Sandu Pharmaceuticals Ltd
SANDUPHQSandu Pharmaceuticals Ltd
SANDUPHQ
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 37.62 | 1.47 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 56.08 | 11.13 | 1.29% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sandu Pharmaceuticals is engaged in manufacturing and marketing of ayurvedic medicine
Peers
Compare with peersGodrej Consumer Products Ltd
Dabur India Ltd
Colgate-Palmolive (India) Ltd
Marico Ltd
Procter & Gamble Hygiene and Health Care Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 46.20 | 43.38 | 49.14 | 49.99 | 48.82 | 58.95 | 65.58 | 65.68 | 67.70 | 67.15 | ||||||||||
Raw Materials | 21.86 | 24.83 | 29.36 | 26.91 | 26.15 | 31.11 | 62.63 | 34.27 | 64.99 | 64.33 | ||||||||||
| Power & Fuel Cost | 0.40 | 0.23 | 0.32 | 0.33 | 0.33 | 0.33 | 0.39 | |||||||||||||
| Employee Cost | 4.51 | 5.42 | 5.94 | 6.49 | 6.85 | 8.02 | 11.10 | |||||||||||||
| Selling & Administrative Expenses | 15.70 | 6.31 | 8.19 | 10.79 | 10.28 | 8.31 | 13.75 | |||||||||||||
| Operating & Other expenses | 0.71 | 4.18 | 2.75 | 2.81 | 3.31 | 8.83 | 3.35 | |||||||||||||
EBITDA | 3.02 | 2.41 | 2.58 | 2.66 | 1.90 | 2.35 | 2.95 | 2.82 | 2.71 | 2.82 | ||||||||||
| Depreciation/Amortization | 0.69 | 0.87 | 0.60 | 0.64 | 0.55 | 0.56 | 0.53 | 0.52 | 0.58 | 0.62 | ||||||||||
| PBIT | 2.33 | 1.54 | 1.98 | 2.02 | 1.35 | 1.79 | 2.42 | 2.30 | 2.13 | 2.20 | ||||||||||
| Interest & Other Items | 1.64 | 1.49 | 1.23 | 1.01 | 0.43 | 0.11 | 0.11 | 0.08 | 0.06 | 0.06 | ||||||||||
| PBT | 0.69 | 0.05 | 0.75 | 1.01 | 0.92 | 1.68 | 2.31 | 2.22 | 2.07 | 2.14 | ||||||||||
| Taxes & Other Items | 0.15 | 0.50 | 0.20 | 0.35 | 0.20 | 0.59 | 0.73 | 0.69 | 0.61 | 0.61 | ||||||||||
| Net Income | 0.54 | -0.45 | 0.55 | 0.66 | 0.72 | 1.09 | 1.58 | 1.53 | 1.46 | 1.53 | ||||||||||
| EPS | 0.76 | -0.64 | 0.78 | 0.93 | 1.02 | 1.45 | 1.99 | 1.66 | 1.51 | 1.58 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | — | 0.00 | 0.00 | 0.75 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.00 | 0.00 | 0.00 | 0.47 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Consumer StaplesFMCG - Personal Products
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sandu Pharmaceuticals Ltd | 39.42 | 1.47 | — |
| Godrej Consumer Products Ltd | -269.47 | 11.99 | 0.68% |
| Dabur India Ltd | 61.96 | 11.08 | 0.85% |
| Colgate-Palmolive (India) Ltd | 74.12 | 52.34 | 1.19% |
Price Comparison
Compare SANDUPHQ with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Dividend/Share
₹0.80
Ex DateEx Date
Sep 19, 2024
Past Dividends
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹0.75
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 23, 2022
Dividend/Share
₹0.75
Ex DateEx Date
Sep 23, 2022
Cash Dividend
Ex DateEx DateSep 22, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 22, 2021
Sandu Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 12 August 2024, inter alia, have recommended the final dividend of Rs 0.8 per equity Share (i.e. 8%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Net profit of Sandu Pharmaceuticals rose 54.55% to Rs 0.17 crore in the quarter ended June 2024 as against Rs 0.11 crore during the previous quarter ended June 2023. Sales declined 3.45% to Rs 17.05 crore in the quarter ended June 2024 as against Rs 17.66 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales17.0517.66 -3 OPM %2.402.04 - PBDT0.430.33 30 PBT0.270.21 29 NP0.170.11 55 Powered by Capital Market - Live
Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Why are shares of JP Associates, Va Tech Wabag, JP Power, Rail Vikas Nigam and Sandu Pharma, rallying today?
Board of Board of Sandu Pharmaceuticals recommends revised final dividend
Sandu Pharma chairman passes away
Sandu Pharmaceuticals’ Goa plant suffers fire accident due to cyclone Tauktae
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 6.25%, vs industry avg of 6.71%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.12% to 0.11%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 17.21%, vs industry avg of -2.38%